Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk’s obesity ...
The combination of ervogastat plus clesacostat was more effective at resolving metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis in patients with biopsy-confirmed MASH ...
Wegovy has been approved for use among the growing number of Americans who have MASH. By Dani Blum The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly ...
Wegovy is first GLP-1 treatment approved for MASH FDA decision based on part one of an ongoing study Novo Nordisk seeks approval in Europe and Japan Aug 15 (Reuters) - Novo Nordisk (NOVOb.CO), opens ...
Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback